miR‐506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing <scp>MDR</scp>1/P‐gp expression

Zhou, Hui; Lin, Changwei; Zhang, Yi; Zhang, Xiuzhong; Zhang, Chong; Zhang, Pengbo; Xie, Xingwang; Ren, Zeqiang

doi:10.1111/cpr.12341

Cited by 82 publications

(63 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besse et al () found that MDR1 overexpression was the most important change in carfilzomib‐resistant multiple myeloma cells. Moreover, many studies proved that there was positive relationship between MDR1 and the resistance to various drugs in CC treatment, such as doxorubicin (Du et al, ; Yan, Zhao, & Zhang, ), oxaliplatin (Zhou et al, ), and irinotecan (Paule et al, ). In this study, qPCR data further demonstrated that FOXO3 overexpression had little effects on the expression of other five members of ATP‐binding cassette family in HCT116 cells, including ABCB2, ABCA1, ABCA2, ABCG1, and ABCG2 (Figure ).…”

Section: Discussionmentioning

confidence: 99%

Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression

Gao

Liu

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Globally, colon cancer (CC) is the third reason of tumor‐related deaths. Previous reports indicate that Forkhead box O3 (FOXO3) is involved in the development of various tumors and may have different effects depending upon the types of tumors. Hence, this study was to examine the effects of FOXO3 on CC cells and uncover the possible mechanisms. Methods MTT and cell count assay were applied to analyze the viability of transfected CC cells. rVista, dual luciferase reporter assay, and chromatin immunoprecipitation assay were used to identify the downstream target of FOXO3 in HCT116 cells. The mRNA and protein abundance of FOXO3 and MDR1 were determined by quantitative PCR and Western blot, respectively. Results Forkhead box O3 stimulated the proliferation of both HCT116 and DLD1 cells. Moreover, FOXO3 overexpression inhibited doxorubicin sensitivity of HCT116 cells, while the knockout of FOXO3 by FOXO3 shRNA restored the doxorubicin sensitivity in doxorubicin‐resistant HCT116 DR cells. Next, we found that FOXO3 directly bound to the promoter of MDR1 and enhanced MDR1 expression in HCT116 cells. MDR1 overexpression enhanced the viability and doxorubicin resistance of CC cells. Besides, MDR1 overexpression plasmid significantly abrogated the decrease in cell proliferation and resistance of HCT116 cells to doxorubicin caused by FOXO3 knockout. Conclusion Forkhead box O3 exhibited promotive effects on the proliferation and doxorubicin resistance in CC cells via targeting MDR1.

show abstract

Section: Discussionmentioning

confidence: 99%

Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression

Gao

Liu

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

show abstract

“…Furthermore, Zhou et al demonstrated that miR‐506 overexpression increases oxaliplatin sensitivity in oxaliplatin‐resistant CRC cells by inhibiting P‐gp expression via downregulation of the Wnt/β‐catenin signaling. They suggested that miR‐506 could be used to develop miRNAs‐based strategies to reduce oxaliplatin resistance …”

Section: Micrornas Drug Accumulation and Oxaliplatin Resistancementioning

confidence: 99%

“…It has been shown that overexpression of miR‐506 downregulates Wnt/β‐catenin signaling pathway and enhances oxaliplatin sensitivity. In addition downregulation of Wnt/β‐catenin signaling pathway by miR‐506 caused inhibiting of the expression of two common drug resistance proteins including multidrug resistance‐associated protein 1 (MRP1) and permeability‐glycoprotein (P‐gp) . Similarly, miR‐204‐5p enhances the chemotherapeutic sensitivity but through downregulation of RAB22A (a member of the RAS oncogene family) …”

Section: Micrornas Signaling Pathway Transcription Factors and Oxamentioning

confidence: 99%

“…They suggested that miR-506 could be used to develop miRNAs-based strategies to reduce oxaliplatin resistance. 57 Multidrug resistance-associated protein 2 (MRP2) or ABCC2 is another important ABC protein in platinum-drugresistance cells. An increased expression of ABCC2 has been observed in adenomas with mild to moderate dysplasia, and is among the early events in the colorectal adenomacarcinoma development sequence.…”

Section: Micrornas Drug Accumulation and Oxaliplatin Resistancementioning

confidence: 99%

“…In addition downregulation of Wnt/β-catenin signaling pathway by miR-506 caused inhibiting of the expression of two common drug resistance proteins including multidrug resistance-associated protein 1 (MRP1) and permeability-glycoprotein (P-gp). 57 Similarly, miR-204-5p enhances the chemotherapeutic sensitivity but through downregulation of RAB22A (a member of the RAS oncogene family). 71 A number of signaling pathways involved in tumorigenesis, including phosphatidylinositol 3-kinase Ser/Thr kinase pathway (PI3K/Akt), and the RAF kinase/mitogen activated protein kinase (RAF/MAPK) pathway, are activated by insulin-like growth factor-I receptor (IGF-IR).…”

Section: Micrornas Signaling Pathway Transcription Factors and Omentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication

et al. 2019

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common malignancies with poor prognosis. Oxaliplatin‐based chemotherapy is an important treatment for CRC; however, the cells develop resistance to therapy. The mechanisms underlying oxaliplatin resistance are complex and unclear. There is increasing evidence that microRNAs (miRNAs) (i.e., miR‐34a, miR‐143, miR‐153, miR‐27a, miR‐218, and miR‐520) play an essential role in tumorigenesis and chemotherapy resistance, by targeting various cellular and molecular pathways (i.e., PI3K/Akt/Wnt, EMT, p53, p21, and ATM) that are involved in the pathogenesis of CRC. Identifying the miRNAs that are involved in chemo‐resistance, and their function, may help as a potential therapeutic option for treatment of CRC or as potential prognostic biomarker. Here, we summarized the clinical impact of miRNAs that have critical roles in the development of resistance to oxaliplatin in CRC.

show abstract

Novel strategies to reverse chemoresistance in colorectal cancer

Zhang

Yan

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a common gastrointestinal malignancy with high morbidity and fatality. Chemotherapy, as traditional therapy for CRC, has exerted well antitumor effect and greatly improved the survival of CRC patients.Nevertheless, chemoresistance is one of the major problems during chemotherapy for CRC and significantly limits the efficacy of the treatment and influences the prognosis of patients. To overcome chemoresistance in CRC, many strategies are being investigated. Here, we review the common and novel measures to combat the resistance, including drug repurposing (nonsteroidal anti-inflammatory drugs, metformin, dichloroacetate, enalapril, ivermectin, bazedoxifene, melatonin, and S-adenosylmethionine), gene therapy (ribozymes, RNAi, CRISPR/ Cas9, epigenetic therapy, antisense oligonucleotides, and noncoding RNAs), protein inhibitor (EFGR inhibitor, S1PR2 inhibitor, and DNA methyltransferase inhibitor), natural herbal compounds (polyphenols, terpenoids, quinones, alkaloids, and sterols), new drug delivery system (nanocarriers, liposomes, exosomes, and hydrogels), and combination therapy. These common or novel strategies for the reversal of chemoresistance promise to improve the treatment of CRC.

show abstract

miR‐506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P‐gp expression

Cited by 82 publications

References 31 publications

Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression

Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression

MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication

Novel strategies to reverse chemoresistance in colorectal cancer

Contact Info

Product

Resources

About